000850909 001__ 850909
000850909 005__ 20210129234650.0
000850909 037__ $$aFZJ-2018-04643
000850909 1001_ $$0P:(DE-Juel1)143792$$aGalldiks, Norbert$$b0$$ufzj
000850909 1112_ $$aJahrestagung der Deutschen Gesellschaft für Nuklearmedizin 2018$$cBremen$$d2018-04-18 - 2018-04-21$$wGermany
000850909 245__ $$aPhotopenic defects on O-(2-18F-fluoroethyl)-L-tyrosine PET - clinical relevance in glioma patients.
000850909 260__ $$c2018
000850909 3367_ $$0PUB:(DE-HGF)1$$2PUB:(DE-HGF)$$aAbstract$$babstract$$mabstract$$s1533214482_28050
000850909 3367_ $$033$$2EndNote$$aConference Paper
000850909 3367_ $$2BibTeX$$aINPROCEEDINGS
000850909 3367_ $$2DRIVER$$aconferenceObject
000850909 3367_ $$2DataCite$$aOutput Types/Conference Abstract
000850909 3367_ $$2ORCID$$aOTHER
000850909 520__ $$aV48Photopenic defects on O-(2-18F-fluoroethyl)-L-tyrosine PET - clinical relevance in glioma patientsN. Galldiks1, M. Unterrainer2, N. Judov3, G. Stoffels3, M. Rapp4, P. Lohmann3, F. Vettermann2, V. Dunkl1, B. Suchorska5, J. C. Tonn5, F. W. Kreth5, G. R. Fink1, P. Bartenstein2, K. J. Langen3, N. L. Albert21Uniklinik Köln, Klinik für Neurologie, Köln; 2Uniklinik München (LMU), Klinik für Nuklearmedizin, München; 3Forschungszentrum Jülich, Inst. für Neurowissenschaften und Medizin (INM-4), Jülich; 4Uniklinik Düsseldorf, Klinik für Neurochirurgie, Düsseldorf; 5Uniklinik München (LMU), Klinik für Neurochirurgie, MünchenZiel/Aim:In PET imaging, a fraction of approximately 5-10% of cerebral gliomas show no increased accumulation of O-(2-18F-fluoroethyl)-L-tyrosine (FET) compared to the normal brain. Some of these lesions present even as photopenic defects. The clinical relevance of this phenomenon remains to be elucidated.Methodik/Methods:Glioma patients with a negative FET PET scan prior to histological confirmation were retrospectively identified in three university centers. Gliomas were visually rated as having indifferent FET uptake or as photopenic when FET uptake was below background acitivity. For quantitative analysis, FET uptake in the area of signal hyperintensity on the T2-/FLAIR-weighted MRI was evaluated by mean standardized uptake values (SUV) and mean tumor-to-brain ratios (TBR). In patients without treatment (“watch and wait” strategy), the progression-free survival (PFS) of photopenic gliomas was compared with that of gliomas with indifferent FET uptake.Ergebnisse/Results:Of 104 FET-negative gliomas (2 WHO grade I, 75 WHO grade II, 23 WHO grade III, and 4 WHO grade IV), 36 cases with photopenic defects (35%) were identified (23 WHO grade II, 12 WHO grade III, and one glioblastoma). FET uptake in photopenic defects was significantly decreased compared to both the healthy-appearing brain tissue (SUV, 0.88±0.23 vs. 1.10±0.26; P<0.001) and gliomas with indifferent FET uptake (TBR, 0.83±0.10 vs. 1.03±0.11; P<0.001). In patients without treatment (all WHO grade II; stereotactic biopsy only), PFS of those with indifferent FET uptake (n=16) was significantly longer than with photopenic defects (n=10) (31 vs. 23 months; P=0.026). Patients’ age and rate of IDH mutations did not differ significantly (P>0.05).Schlussfolgerungen/Conclusions:Around one-third of FET-negative gliomas exhibit photopenic defects. These photopenic gliomas should be managed more actively as they might have a higher risk for harboring a higher-grade glioma and an unfavorable outcome compared to gliomas with indifferent FET uptake.
000850909 536__ $$0G:(DE-HGF)POF3-572$$a572 - (Dys-)function and Plasticity (POF3-572)$$cPOF3-572$$fPOF III$$x0
000850909 7001_ $$0P:(DE-HGF)0$$aUnterrainer, M.$$b1
000850909 7001_ $$0P:(DE-Juel1)143958$$aJudov, N.$$b2$$ufzj
000850909 7001_ $$0P:(DE-Juel1)131627$$aStoffels, G.$$b3$$ufzj
000850909 7001_ $$0P:(DE-Juel1)145110$$aLohmann, P.$$b4$$ufzj
000850909 7001_ $$0P:(DE-HGF)0$$aVettermann, F.$$b5
000850909 7001_ $$0P:(DE-Juel1)156211$$aDunkl, V.$$b6
000850909 7001_ $$0P:(DE-HGF)0$$aSuchorska, B.$$b7
000850909 7001_ $$0P:(DE-HGF)0$$aTonn, J. C.$$b8
000850909 7001_ $$0P:(DE-HGF)0$$aKreth, F. W.$$b9
000850909 7001_ $$0P:(DE-Juel1)131720$$aFink, G. R.$$b10$$ufzj
000850909 7001_ $$0P:(DE-HGF)0$$aBartenstein, P.$$b11
000850909 7001_ $$0P:(DE-Juel1)131777$$aLangen, K. J.$$b12$$ufzj
000850909 7001_ $$0P:(DE-HGF)0$$aAlbert, N. L.$$b13
000850909 8564_ $$uhttps://www.nuklearmedizin.de/jahrestagungen/abstr_online2018/abstract_detail.php?navId=220&aId=97
000850909 909CO $$ooai:juser.fz-juelich.de:850909$$pVDB
000850909 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich$$b0$$kFZJ
000850909 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143958$$aForschungszentrum Jülich$$b2$$kFZJ
000850909 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131627$$aForschungszentrum Jülich$$b3$$kFZJ
000850909 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)145110$$aForschungszentrum Jülich$$b4$$kFZJ
000850909 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131720$$aForschungszentrum Jülich$$b10$$kFZJ
000850909 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131777$$aForschungszentrum Jülich$$b12$$kFZJ
000850909 9131_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000850909 9141_ $$y2018
000850909 920__ $$lyes
000850909 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000850909 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x1
000850909 980__ $$aabstract
000850909 980__ $$aVDB
000850909 980__ $$aI:(DE-Juel1)INM-3-20090406
000850909 980__ $$aI:(DE-Juel1)INM-4-20090406
000850909 980__ $$aUNRESTRICTED